Managing respiratory complications in infants and newborns with congenital diaphragmatic hernia

IF 0.8 4区 医学 Q4 PHARMACOLOGY & PHARMACY
S. Shetty, Fahad M. S. Arattu Thodika, A. Greenough
{"title":"Managing respiratory complications in infants and newborns with congenital diaphragmatic hernia","authors":"S. Shetty, Fahad M. S. Arattu Thodika, A. Greenough","doi":"10.1080/21678707.2020.1865915","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction: Congenital diaphragmatic hernia (CDH) is one of the most challenging neonatal surgical conditions due to its high mortality and morbidity. A multidisciplinary approach is required regarding the management of affected infants, before birth, during their initial hospitalization and in their long-term follow-up. Areas covered: This review discusses the monitoring and management strategies for infants with CDH including during the prenatal and postnatal periods. It emphasizes the long-term sequelae these patients can suffer throughout childhood and adulthood. This article highlights the progress that has been made and where future developments have the potential to improve the outcome of this vulnerable patient population. A literature search was performed using Google Scholar, Science Direct and PubMed. Expert opinion: Advances in antenatal and neonatal care have improved the early survival of infants with CDH, but many infants are surviving with long-term morbidity. An increasing number of CDH survivors are now reaching adolescence and adulthood. New challenges arise regarding the prevention and management of their long-term problems.","PeriodicalId":12118,"journal":{"name":"Expert Opinion on Orphan Drugs","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21678707.2020.1865915","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Orphan Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678707.2020.1865915","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

ABSTRACT Introduction: Congenital diaphragmatic hernia (CDH) is one of the most challenging neonatal surgical conditions due to its high mortality and morbidity. A multidisciplinary approach is required regarding the management of affected infants, before birth, during their initial hospitalization and in their long-term follow-up. Areas covered: This review discusses the monitoring and management strategies for infants with CDH including during the prenatal and postnatal periods. It emphasizes the long-term sequelae these patients can suffer throughout childhood and adulthood. This article highlights the progress that has been made and where future developments have the potential to improve the outcome of this vulnerable patient population. A literature search was performed using Google Scholar, Science Direct and PubMed. Expert opinion: Advances in antenatal and neonatal care have improved the early survival of infants with CDH, but many infants are surviving with long-term morbidity. An increasing number of CDH survivors are now reaching adolescence and adulthood. New challenges arise regarding the prevention and management of their long-term problems.
先天性膈疝婴儿和新生儿呼吸系统并发症的处理
摘要简介:先天性膈疝(CDH)因其高死亡率和高发病率而成为最具挑战性的新生儿手术条件之一。需要对受影响婴儿在出生前、初次住院期间和长期随访期间的管理采取多学科方法。涵盖的领域:本综述讨论了CDH婴儿的监测和管理策略,包括产前和产后。它强调了这些患者在整个童年和成年期可能遭受的长期后遗症。这篇文章强调了已经取得的进展,以及未来的发展有可能改善这一弱势患者群体的结果。使用Google Scholar、Science Direct和PubMed进行文献检索。专家意见:产前和新生儿护理的进步提高了CDH婴儿的早期存活率,但许多婴儿在长期发病的情况下存活下来。越来越多的CDH幸存者现在正进入青春期和成年期。在预防和管理其长期问题方面出现了新的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Opinion on Orphan Drugs
Expert Opinion on Orphan Drugs PHARMACOLOGY & PHARMACY-
CiteScore
2.30
自引率
0.00%
发文量
8
期刊介绍: Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信